Fusion generates target specific antibodies from protein antigens with the capability, to modify their characteristics to increase efficacy.
The Company has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology) which accelerates the validation of targets from DNA sequence through to recombinant protein expression. Fusion generates target specific antibodies from protein antigens with the capability, to modify their characteristics to increase efficacy.
The company also provides a range of services to leading pharmaceutical companies worldwide from its laboratories in Belfast.
Fusion generates target specific antibodies from protein antigens with the capability, to modify their characteristics to increase efficacy.